➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Mallinckrodt
McKinsey
Medtronic
Baxter

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLUOROESTRADIOL F-18

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Fluoroestradiol F-18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01153672 Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy Active, not recruiting National Cancer Institute (NCI) N/A 2010-11-01 This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug
NCT01153672 Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy Active, not recruiting University of Washington N/A 2010-11-01 This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug
NCT01627704 Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer Completed Assistance Publique - Hôpitaux de Paris N/A 2012-06-01 Compare the response rate after 6 months of hormone treatment (or a major change in hormone treatment) in metastatic breast cancer, according to the uptake of FES in metastatic lesions taking-up FDG on PET/CT at baseline. Hypothesis: best response rate will be observed in patients with all metastases taking up FES prior to treatment.
NCT01714128 FES-PET for Patients Treated on NCI Protocol 8762 Withdrawn Washington University School of Medicine N/A 2013-06-01 A significant number of all invasive breast cancers are hormone sensitive and may be candidates for treatment with hormonal therapy. This project will assess the ability and usefulness of imaging hormone-receptor status in breast cancer with positron emission tomography (PET) and 6α-[18F]fluoro-17β-estradiol (FES), an estrogen analogue in patients who are scheduled to be treated with hormonal therapy given in combination with a selective allosteric inhibitor of AKT protein kinase (MK2206) .
NCT01720602 Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy Active, not recruiting National Cancer Institute (NCI) N/A 2012-11-01 This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fluoroestradiol F-18

Condition Name

Condition Name for Fluoroestradiol F-18
Intervention Trials
Breast Cancer 4
Stage IV Breast Cancer 4
Metastatic Breast Cancer 3
Recurrent Breast Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fluoroestradiol F-18
Intervention Trials
Breast Neoplasms 14
Breast Neoplasms, Male 2
Hypertension 1
Ovarian Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluoroestradiol F-18

Trials by Country

Trials by Country for Fluoroestradiol F-18
Location Trials
United States 13
China 2
France 1
Canada 1
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fluoroestradiol F-18
Location Trials
Washington 4
Pennsylvania 3
Wisconsin 2
North Carolina 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluoroestradiol F-18

Clinical Trial Phase

Clinical Trial Phase for Fluoroestradiol F-18
Clinical Trial Phase Trials
Phase 3 1
Phase 2 5
Phase 1/Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fluoroestradiol F-18
Clinical Trial Phase Trials
Recruiting 7
Not yet recruiting 6
Completed 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluoroestradiol F-18

Sponsor Name

Sponsor Name for Fluoroestradiol F-18
Sponsor Trials
University of Washington 3
National Cancer Institute (NCI) 3
University of Pennsylvania 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fluoroestradiol F-18
Sponsor Trials
Other 18
NIH 3
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Baxter
Merck
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.